PE-22-28
PE-22-28 is a shortened spadin analogue from preclinical TREK-1 research.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
PE-22-28 is the shortened spadin analogue defined in the cited primary study; unspecified commercial products are not thereby analytically confirmed.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
Research examined channel activity, stability and mouse behavioral models.
- Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activityAnimal study2017
Moha ou Maati H et al.
Accessed:
Research gaps
- ·A mouse behavioral test does not establish effective antidepressant treatment in humans; no human study was established.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
It inhibits the TREK-1 potassium channel in experimental systems.
- Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activityAnimal study2017
Moha ou Maati H et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Clinical pharmacokinetics, toxicology, contraindications and interactions have not been adequately studied.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·A mouse behavioral test does not establish effective antidepressant treatment in humans; no human study was established.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activityAnimal study2017
Moha ou Maati H et al.
Accessed:
Sources
Sources checked: · Version 3
- Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activityAnimal study2017
Moha ou Maati H et al.
Accessed: